Modafinil wake-promoting agents

Engber T. M., Koury E. J., Dennis S. A. et al. (1998). Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci. Lett. 241, 95-8. 

Engber, T.M., Dennis, S.A., Jones, B.E., Miller, MS, Contreras, PC. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat comparison with amphetamine. Neuroscience 1998 87(4) 905-911. 

Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P (2004) Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus an in vitro pharmacologic study. Sleep 27 19-25... 

Modafinil another wakefulness promoting agent with an unknown mechanism of action used for narcolepsy in adults and being studied for use in children at present dose range is 1 Of MOO mg/day divided bid. Side effects include headaches, anxiety, nausea and nervousness. 

Modafinil is a wake-promoting agent whose specific biochemical mechanism of action is obscure. It increases brain concentrations of dopamine after chronic administration in animals but has no overtly stimulant effect like amphetamines. It appears to have a slow onset and its action lasts 8-12 h abuse potential is very low. Modafinil is used in narcolepsy and other hypersomnias and has also been studied in normal people who need to stay awake for long periods and fimction well. 

Modafinil is a benzhydrylsulfinylacetamide wake-promoting agent for oral administration (1). It selectively targets neuronal pathways in the sleep/wake centers of the brain. It is well absorbed and its half-life is about 12-15 hours, which largely reflects the half-life of its levorotatory enantiomer. It... 

Modafanil, a racemic compound unrelated to psychostimulants, is the current standard for the treatment of EDS. Modafinil selectively targets neuronal pathways in the hypothalamus that regulate the normal sleep-wake cycle. The precise mechanism by which modafinil promotes wakefulness is unknown. Modafinil is readily absorbed, reaches peak plasma concentrations in 2 to 4 hours, and has a half-life of 15 hours. The dose is between 200 and 400 mg/day. The efficacy of modahnil in treating EDS has been demonstrated in several randomized studies. EDS may also be treated with stimulants to improve alertness and to increase daytime performance. Cataplexy is not signihcantly treated with modafinil and must be treated with anticataplectic agents." ... 

---